BioCentury | May 21, 2012
Clinical News

GM-CT-01: Phase I/II started

...to evaluate IV GM-CT-01 every 3 days in combination with a peptide vaccine from the Ludwig Institute for Cancer Research (LICR)...
BioCentury | May 7, 2012
Financial News

iTeos Therapeutics completes venture financing

...Belgium Business: Cancer Date completed: 5/3/12 Type: Venture financing Raised: €3 million ($4 million) Investors: Ludwig Institute for Cancer Research (LICR)...
BioCentury | May 4, 2012
Financial News

Belgium-based iTeos debuts to focus on cancer immunotherapy

...Belgium) debuted on Thursday with a EUR 3 million ($4 million) series A round from Ludwig Institute for Cancer Research (LICR)...
Items per page:
1 - 3 of 3
BioCentury | May 21, 2012
Clinical News

GM-CT-01: Phase I/II started

...to evaluate IV GM-CT-01 every 3 days in combination with a peptide vaccine from the Ludwig Institute for Cancer Research (LICR)...
BioCentury | May 7, 2012
Financial News

iTeos Therapeutics completes venture financing

...Belgium Business: Cancer Date completed: 5/3/12 Type: Venture financing Raised: €3 million ($4 million) Investors: Ludwig Institute for Cancer Research (LICR)...
BioCentury | May 4, 2012
Financial News

Belgium-based iTeos debuts to focus on cancer immunotherapy

...Belgium) debuted on Thursday with a EUR 3 million ($4 million) series A round from Ludwig Institute for Cancer Research (LICR)...
Items per page:
1 - 3 of 3